BRISTOL, Tenn. — GlaxoSmithKline will begin laying off its workforce at a drug-manufacturing plant in Bristol in April 2009 and shutter the plant by Oct. 31, the company said Wednesday.
The 400,000-square-foot plant makes the penicillin drug Augmentin.
GSK first announced plans in 2006 to close the plant due to declining sales of Augmentin. The plant currently employs 236 people. At its peak, the plant had more than 400 workers, according to the Herald-Courier newspaper in Bristol.
GlaxoSmithKline to Close Tennessee Plant by 2009
Copyright 2008 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
-
- PC makers may face a legal challenge in ‘Green Dam’ battle from U.S. firm
Jul. 3, 2009 - As Nortel’s final demise nears, what blame should its board shoulder?
Jul. 3, 2009 - Climate change and the economy: Public policies like ‘cap and trade’ and a carbon tax could have big impacts on our wallets.
Jul. 3, 2009 - 20/20: Surgery can let you see like a child again
Jul. 3, 2009 |
- CDC: US swine flu cases rise to nearly 34,000
Jul. 3, 2009
- PC makers may face a legal challenge in ‘Green Dam’ battle from U.S. firm
-
- RTP-based Metabolon raises another $1 million in venture capital
Jul. 2, 2009 - NanoCor Therapeutics raises $2.5M
Jul. 1, 2009 - Despite three IPOs, venture-backed exits drop to trickle in second quarter
Jul. 1, 2009 - Seeking investors? Be sure to find the right angel partners
Jul. 1, 2009 - Georgia Research Alliance venture fund closes on $18.75 million
Jun. 29, 2009
- RTP-based Metabolon raises another $1 million in venture capital
More from wrallocaltechwire.com
Market Watch
advertisement


